This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics. Pivotal trials on LMN-201 are expected to commence in 2023.
This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine.
Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. GSK said it is paying $2.1
Last year, Pfizer made almost $6 billion from its Prevnar 13 vaccine, which covers 13 common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. That is equivalent to 14% of Pfizer’s total revenues.
Pseudomonas aeruginosa, a common environmental bacterium, can colonize different body parts, such as the lungs, leading to persistent, chronic infections that can last a lifetime – a common occurrence in people with cystic fibrosis. “Our study took a novel approach to look directly into the bacterium’s behavior in the human host.”
Anthrax is a rare, yet severe disease caused by the bacterium B. The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. What Is Anthrax?
To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments). Moreover, the response did not induce symptoms typical of a food allergy.
The outbreak was caused by the bacterium Listeria monocytogenes , which was found in several samples of Blue Bell ice cream products, as well as in the company’s manufacturing facilities. coli O157:H7 bacteria. The outbreak was caused by the bacterium Escherichia coli O157:H7, a strain of E.
Johnson & Johnson’s Top 5 Best-Selling Drugs of 2022: 1) Stelara (ustekinumab) Stelara is an immunosuppressant biologic therapy that blocks the IL-12 and IL-23 proteins that play a role in plaque psoriasis and Crohn’s disease. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells).
SARS-CoV-2 is characterized by an outer surface speckled with spike proteins, giving it a crown-like appearance, hence the name “corona,” which is the Latin word for crown. The spike protein is critical for binding to ACE2 receptors on host cells — this interaction mediates the entry of the virus into cells.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content